NSE: SBILIFE· InsuranceCore · Aug 26Large cap

SBI Life Insurance Company

Lowest-cost, highest-persistency

Last close: ₹1,735.00; 29 Sept 2026 · reference
1D · 1M: +0.4% · −1.5%; price-only
Weight: 1.1%; 31 Jul 2026 · Aug rank 26
Thesis review: 8 Sep 2026; Why We Own, p38

Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗

Map

What must happen → what could break it → what we watch

Catalysts · 3

H1FY27 results (late Oct-2026): margin recovery toward 27-28% guidance as group business normalises and non-par mix stays high.
C1
Monthly IRDAI new-business data (Sep-Oct-2026) confirming 20%+ individual APE growth ahead of peers.
C2
Any IRDAI/GST Council move to restore input-tax credit for insurers, which would reverse the ~120 bps GST margin drag.
C3

Material risks · 3

Bancassurance dependence: SBI channel is ~60% of FY26 APE (47% in Q1FY27); any regulatory cap on banca share or a change in SBI's priorities would cut growth.
R1
ULIP/market sensitivity: ULIPs were 60% of FY26 APE (46% in Q1FY27); an equity-market correction would slow ULIP sales and compress the mix-driven margin, while 61-month persistency fell to 58.4% from 63.6%.
R2
GST/ITC and product regulation: exemption from 22-Sep-2025 with ITC withdrawal cost ~120 bps of Q1FY27 margin (27.4% ex-GST vs 26.2% reported); further surrender-value or commission rules could pressure VNB.
R3

Live monitors

Valuation vs approved target
No target stated
Latest reported quarter
Q Jun-26
Results-driven thresholds
Awaiting approved numbers

Catalysts and risks are the approved one-pager text in full; the register below adds owners and review dates. Monitors read from the price and fundamentals feeds.

Risks as a decision framework

Material risks

Risk register
#	Risk (approved text)	Owner · next review
01	Bancassurance dependence: SBI channel is ~60% of FY26 APE (47% in Q1FY27); any regulatory cap on banca share or a change in SBI's priorities would cut growth.	Research · post 2QFY27
02	ULIP/market sensitivity: ULIPs were 60% of FY26 APE (46% in Q1FY27); an equity-market correction would slow ULIP sales and compress the mix-driven margin, while 61-month persistency fell to 58.4% from 63.6%.	Research · post 2QFY27
03	GST/ITC and product regulation: exemption from 22-Sep-2025 with ITC withdrawal cost ~120 bps of Q1FY27 margin (27.4% ex-GST vs 26.2% reported); further surrender-value or commission rules could pressure VNB.	Research · post 2QFY27

Exposure mechanism, impact and mitigants are as written in the book. Leading indicators and numeric triggers not stated in the approved text remain research tasks rather than being invented.

Catalysts

Observable events

01H1FY27 results (late Oct-2026): margin recovery toward 27-28% guidance as group business normalises and non-par mix stays high.
02Monthly IRDAI new-business data (Sep-Oct-2026) confirming 20%+ individual APE growth ahead of peers.
03Any IRDAI/GST Council move to restore input-tax credit for insurers, which would reverse the ~120 bps GST margin drag.

Monitors

Live monitors from available data

ClearValuation exceeding the approved range: reference close 1,735 vs base target not stated.
DataLatest reported quarter in fundamentals: Q Jun-26. Results-driven monitors (growth below thesis threshold, margin, credit cost) need approved numeric thresholds; none in the book.
DataInput-cost and capital-allocation monitors require licensed commodity/filings feeds — not configured.